Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 17/20 | 0.53 |
| ▸ | JAK3 | P52333 | 17/20 | 0.53 |
| ▸ | GRK6 | P43250 | 1/20 | 0.39 |
| ▸ | PLK4 | O00444 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218817 | 0.83 | JAK2 (0.73) | JAK2JAK3 | |
| SCHEMBL4982579 | 0.81 | JAK2 (0.80) | JAK2JAK3 | |
| SCHEMBL219030 | 0.79 | JAK2 (0.47) | JAK2JAK3NTRK1 | |
| SCHEMBL217138 | 0.77 | JAK2 (0.82) | JAK2JAK3PLK4NTRK1 | |
| SCHEMBL251027 | 0.72 | JAK2 (0.51) | JAK2JAK3 | |
| SCHEMBL3937609 | 0.72 | ALOX15 (0.61) | JAK2JAK3PLK4NTRK1 | |
| SCHEMBL220017 | 0.71 | JAK3 (0.88) | JAK2JAK3PLK4NTRK1 | |
| SCHEMBL3638000 | 0.69 | RAF1 (0.49) | JAK2JAK3 | |
| SCHEMBL220721 | 0.68 | JAK3 (0.79) | JAK2JAK3NTRK1 | |
| SCHEMBL4009997 | 0.67 | JAK3 (0.57) | JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287475-A1 | 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287475-A1 | 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer | ABL1, FLT3, ERBB2 | JAK2 35/4885JAK3 13/4885GRK6 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.